Cargando…

The effects of Tim-3 activation on T-cells in gastric cancer progression

The incidence of gastric cancer is high, especially in China. The present study aims to provide a novel therapeutic target for gastric cancer. Peripheral blood, cancerous and paracancerous tissues were collected from patients with gastric cancer. T-cell immunoglobulin mucin domain-3 (Tim-3) expressi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Jiangtao, Zhang, Huanhu, Sun, Shengbo, Sun, Shaowei, Li, Leping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2019
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341528/ https://www.ncbi.nlm.nih.gov/pubmed/30675200 http://dx.doi.org/10.3892/ol.2018.9743

Ejemplares similares

Long-term outcomes of laparoscopic Extralevator Abdominoperineal excision with modified position change for low rectal Cancer treatment
por: Sun, Shaowei, et al.
Publicado: (2022)

Cancer cell intrinsic TIM-3 induces glioblastoma progression
por: Guo, Qing, et al.
Publicado: (2022)

TIM-3 Expression Characterizes Regulatory T Cells in Tumor Tissues and Is Associated with Lung Cancer Progression
por: Gao, Xin, et al.
Publicado: (2012)

On the significance of Tim-3 expression in pancreatic cancer
por: Peng, Pu-ji, et al.
Publicado: (2017)

Mast cell activation is enhanced by Tim1:Tim4 interaction but not by Tim-1 antibodies
por: Phong, Binh, et al.
Publicado: (2016)

Tim-3 Up-regulation in Patients with Gastric Cancer and Peptic Ulcer Disease
por: Naghavi-Alhosseini, Mahdieh, et al.
Publicado: (2017)

Tim-3 is upregulated in human colorectal carcinoma and associated with tumor progression
por: Yu, Muming, et al.
Publicado: (2017)

Tim1 and Tim3 are not essential for experimental allergic asthma
por: Barlow, J L, et al.
Publicado: (2011)

Clinical Value of Combined Detection of Serum sTim-3 and Pepsinogen for Gastric Cancer Diagnosis
por: Chen, Lingli, et al.
Publicado: (2021)

TIM-3 expression in breast cancer
por: Burugu, Samantha, et al.
Publicado: (2018)

TIM-3(+) T cells are not exhausted but activated cells in the tumor microenvironment
por: Jie, Hyun-Bae, et al.
Publicado: (2013)

Tim-3: An Activation Marker and Activation Limiter of Innate Immune Cells
por: Han, Gencheng, et al.
Publicado: (2013)

Decreased Galectin-9 and Increased Tim-3 Expression Are Related to Poor Prognosis in Gastric Cancer
por: Jiang, Jing, et al.
Publicado: (2013)

Association of TIM-3 expression with glucose metabolism in Jurkat T cells
por: Lee, Mi Jin, et al.
Publicado: (2020)

Tim-3 expression on peripheral T cell subsets correlates with disease progression in hepatitis B infection
por: Wu, Wei, et al.
Publicado: (2011)

Long non-coding RNA LINC00511 regulates the expression of microRNA-625-5p and activates signal transducers and activators of transcription 3 (STAT3) to accelerate the progression of gastric cancer
por: Cui, Ning, et al.
Publicado: (2021)

Genetic Mutations of Tim-3 Ligand and Exhausted Tim-3(+) CD8(+) T Cells and Survival in Diffuse Large B Cell Lymphoma
por: Zhang, Tingting, et al.
Publicado: (2020)

Long non-coding RNA Lnc-Tim3 exacerbates CD8 T cell exhaustion via binding to Tim-3 and inducing nuclear translocation of Bat3 in HCC
por: Ji, Jie, et al.
Publicado: (2018)

Immune regulation by Tim-3
por: Banerjee, Hridesh, et al.
Publicado: (2018)

Altered expression of Tim family molecules and an imbalanced ratio of Tim-3 to Tim-1 expression in patients with type 1 diabetes
por: Liu, Yikai, et al.
Publicado: (2022)

T Cell Immunoglobulin Mucin Domain (TIM)-3 Promoter Activity in a Human Mast Cell Line
por: Kim, Jung Sik, et al.
Publicado: (2012)

Blockade of TIM3 relieves immunosuppression through reducing regulatory T cells in head and neck cancer
por: Liu, Jian-Feng, et al.
Publicado: (2018)

Corrigendum to “Genetic Mutations of Tim-3 Ligand and Exhausted Tim-3(+) CD8(+) T Cells and Survival in Diffuse Large B Cell Lymphoma”
por: Zhang, Tingting, et al.
Publicado: (2021)

TIM-3 and TIM-1 Could Regulate Decidual γδTCR Bright T Cells during Murine Pregnancy
por: Nörenberg, Jasper, et al.
Publicado: (2019)

TIM-3, a promising target for cancer immunotherapy
por: He, Yayi, et al.
Publicado: (2018)

Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
por: Cai, Letong, et al.
Publicado: (2023)

TIM-3 Expression Is Downregulated on Human NK Cells in Response to Cancer Targets in Synergy with Activation
por: Dao, Tram N., et al.
Publicado: (2020)

Dok-3 deficient mice display different immune clustering and Tim-3 expression
por: Yan, Wenjiang, et al.
Publicado: (2019)

Tim-3 Expression Defines Regulatory T Cells in Human Tumors
por: Yan, Jing, et al.
Publicado: (2013)

Dysregulated T cell expression of TIM3 in multiple sclerosis
por: Koguchi, Ken, et al.
Publicado: (2006)

Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy
por: Yang, Riyao, et al.
Publicado: (2021)

TIM-Finder: A new method for identifying TIM-barrel proteins
por: Si, Jing-Na, et al.
Publicado: (2009)

Tim Burton /
por: Marcos Arza, Marcos
Publicado: (2007)

Tim Lou
por: Lou, Hou Keong
Publicado: (2009)

Apoptosis of tumor infiltrating effector TIM-3+CD8+ T cells in colon cancer
por: Kang, Chiao-Wen, et al.
Publicado: (2015)

Abnormal expression of Tim‐3 antigen on peripheral blood T cells is associated with progressive disease in osteosarcoma patients
por: Liu, Hongliang, et al.
Publicado: (2016)

Differential expression of TIM-3 between primary and metastatic sites in renal cell carcinoma
por: Zhang, Xingming, et al.
Publicado: (2019)

TIM3(+)FOXP3(+) regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer
por: Sakuishi, Kaori, et al.
Publicado: (2013)

The Role of TIM-3 and LAG-3 in the Microenvironment and Immunotherapy of Ovarian Cancer
por: Kozłowski, Mateusz, et al.
Publicado: (2022)

Correction: Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
por: Cai, Letong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4baohs1enkj9bmp6ojga7gc4pg